A unique feature of the CD38 antibodies is that they are composed of heavy chains only, making them more selective, stable ...

Back in 2019, the companies teamed up to develop a successor to their multiple myeloma blockbuster Darzalex, an anti-CD38 antibody. The deal gave J&J the option to license HexaBody-CD38—which ...

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market. A couple of months ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Shares of 2seventy bio, Inc. TSVT gained 5.26% after the company announced a definitive merger agreement with Bristol Myers Squibb BMY. Per the terms of the deal, BMY will acquire all of the ...

The Phase 2 expansion Part B of the study assessed the objective response rate (primary endpoint) of intravenous HexaBody-CD38 versus subcutaneous daratumumab in patients with anti-CD38 antibody ...

BEIJING, CHINA / / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing ...

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...

COPENHAGEN, Denmark, March 10, 2025--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide ...

a proteasome inhibitor and an anti-CD38 monoclonal antibody. In April 2024, the FDA approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after two or ...